Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma)

Trial Profile

Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Pemetrexed (Primary) ; Dexamethasone; Folic acid; Vitamin B12 analogues
  • Indications Brain metastases; Cancer metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 22 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Sep 2009 Planned end date 1 Dec 2015 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top